Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:32 AM
Ignite Modification Date:
2025-12-25 @ 1:32 AM
NCT ID:
NCT00261794
Eligibility Criteria:
Inclusion Criteria:
1. Current DSM-IV diagnoses of schizophrenia or schizoaffective disorder
2. Stable clinical course and antipsychotic treatment on a new generation antipsychotic other than clozapine and/or a dose of first generation antipsychotic equivalent to 10 mg. or less of haloperidol for one month prior to enrollment
3. Age between 18 and 64 years
4. Voluntary consent after receiving full information about the study
Exclusion Criteria:
1. Documented history of neurological disorder or significant head trauma with extended loss of consciousness
2. Physical limitations (e.g., with hearing or vision) that would interfere substantially with the use of computer-based exercises
3. Current treatment with a first generation antipsychotic medication at a dose equivalent to more than 10 mg. of haloperidol
4. Current treatment with benztropine mesylate at a daily does greater than 4 mg
5. Current treatment with trihexyphenidyl at a daily dose greater than 15 mg
6. Current treatment that combines benztropine mesylate with trihexyphenidyl
7. Current treatment with diphenhydramine
8. Current competitive employment or participation (current or within past 3 months) in a program designed to secure competitive employment (e.g., CWT)
9. Mini Mental Status Examination (MMSE) score of less than 23
10. Diagnosis of current Substance Dependence according to DSM-IV criteria
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
64 Years
Study:
NCT00261794
Study Brief:
Protocol Section:
NCT00261794